(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.17%
@ $6.00
जारी किया गया: 15 Feb 2024 @ 00:52
वापसी: -23.33%
पिछला सिग्नल: Feb 14 - 23:38
पिछला सिग्नल:
वापसी: -5.73 %
Live Chart Being Loaded With Signals
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa...
Stats | |
---|---|
आज की मात्रा | 2.68M |
औसत मात्रा | 592 980 |
बाजार मूल्य | 125.83M |
EPS | $0 ( 2024-04-03 ) |
अगली कमाई की तारीख | ( $-0.470 ) 2024-05-09 |
Last Dividend | $3 706.25 ( 2000-03-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.820 |
ATR14 | $0.0150 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Seshadri Vishwas | Buy | 10 000 | Common Stock |
2024-04-26 | Charles Faith L. | Buy | 7 550 | Common Stock |
2024-04-25 | O'malley Brendan M. | Buy | 8 600 | Common stock |
2024-04-25 | Vazzano Joseph Walter | Buy | 5 608 | Common stock |
2024-03-15 | Vazzano Joseph Walter | Sell | 703 | Common stock |
INSIDER POWER |
---|
82.88 |
Last 95 transactions |
Buy: 4 778 989 | Sell: 610 127 |
मात्रा सहसंबंध
Abeona Therapeutics Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
NVDA | 0.94 |
COOL | 0.939 |
BOTZ | 0.938 |
OPRA | 0.935 |
SVAC | 0.932 |
AVGO | 0.924 |
ADVM | 0.923 |
SMCI | 0.923 |
DFH | 0.922 |
TQQQ | 0.921 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
AMRB | -0.953 |
LWAC | -0.916 |
SOPA | -0.913 |
ONCR | -0.909 |
PHCF | -0.907 |
SRAC | -0.9 |
PRDO | -0.89 |
QTEK | -0.888 |
AGFS | -0.887 |
SQQQ | -0.885 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Abeona Therapeutics Inc सहसंबंध - मुद्रा/वस्त्र
Abeona Therapeutics Inc वित्तीय
Annual | 2023 |
राजस्व: | $3.50M |
सकल लाभ: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2023 |
राजस्व: | $3.50M |
सकल लाभ: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2022 |
राजस्व: | $1.41M |
सकल लाभ: | $964 000 (68.18 %) |
EPS: | $-4.05 |
FY | 2021 |
राजस्व: | $3.00M |
सकल लाभ: | $3.00M (100.00 %) |
EPS: | $-21.57 |
Financial Reports:
No articles found.
Abeona Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $3 706.25 | 2000-03-31 |
Last Dividend | $3 706.25 | 2000-03-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $3 706.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $3.00 | 0.03% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -15.48 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.847 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.34 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.10 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.103 | 1.500 | 4.98 | 7.47 | [0.2 - 2] |
debtRatioTTM | 0.0844 | -1.500 | 8.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -115.31 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.448 | 2.00 | -0.483 | -0.965 | [0 - 30] |
freeCashFlowPerShareTTM | -1.461 | 2.00 | -0.731 | -1.461 | [0 - 20] |
debtEquityRatioTTM | 0.364 | -1.500 | 8.54 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0863 | 1.000 | -1.895 | -1.895 | [0.2 - 0.8] |
operatingProfitMarginTTM | -13.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -6.85 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0547 | 0.800 | -2.97 | -2.38 | [0.5 - 2] |
Total Score | -2.42 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.17 | 1.000 | -0.320 | 0 | [1 - 100] |
returnOnEquityTTM | -3.34 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.461 | 2.00 | -0.487 | -1.461 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.448 | 2.00 | -0.483 | -0.965 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.101 | 1.500 | -2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -10.57 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.63 |
Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं